TY - JOUR ID - 96035 TI - Kit formulation of active pharmaceutical ingredient d,l-HMPAO as a brain perfusion diagnostic system JO - Progress in Chemical and Biochemical Research JA - PCBR LA - en SN - 2676-7090 AU - Davarpanah, Mohammadreza AU - Abbasi, Hossein AU - Nabati, Mehdi AU - Sabahnoo, Hamideh AU - Bodaghi-Namileh, Vida AU - Mazidi, Mohammad AU - Movahhed-Tazehkand, Hossein AU - Mohammadnejad-Mehrabani, Hossein AD - Synthesis and Molecular Simulation Laboratory, Chemistry Department, Pars Isotope Company, P.O. Box: 1437663181, Tehran, Iran Y1 - 2019 PY - 2019 VL - 2 IS - 4 SP - 185 EP - 191 KW - Exametazime KW - HMPAO KW - Kit Formulation KW - Nuclear medicine KW - Radiopharmaceutical KW - Technetium-99m radionuclide DO - 10.33945/SAMI/PCBR.2019.4.4 N2 - The purpose of this research study is to prepare Exametazime (d,l-HMPAO) kit for labeling with 99m-technetium radionuclide as a brain perfusion diagnostic system. In first step, the active pharmaceutical ingredient d,l-HMPAO was prepared in two steps with the purity of 99.29 %. Its molecular structure was characterized using elemental analysis, Fourier-transform infrared spectroscopy (FT-IR) and nuclear magnetic resonance (NMR) technique. In second step, the d,l-HMPAO kit was prepared using six different formulations and labeled by technetium-99m radionuclide. The high radiochemical yield was attributed to the high amount of SnCl2 and adding phosphate buffer. The animal studies were conducted on three-month old male Wistar rats. The biodistribution studies revealed that, the mean activity in brain of all rats was above 1% ID/g. This showed the high isomerism purity of the synthesized compound (d,l-HMPAO) and optimization of the suggested formulations. UR - https://www.pcbiochemres.com/article_96035.html L1 - https://www.pcbiochemres.com/article_96035_c7f32b5375f99d3a1fdaac30f6872c6f.pdf ER -